Access

Business

Nature 441, 689 (8 June 2006) | doi:10.1038/441689a; Published online 7 June 2006

Biochemist strikes gold

Meredith Wadman

Top

Merck is tapping into academic research in its hunt for drug candidates. Meredith Wadman reports on the company's latest deal with Harvard.

It's the stuff of academics' daydreams: do the science that opens a route to drugs for a common, debilitating and, so far, untreatable condition. Then have a megacompany swoop in and pay you handsomely for the privilege of — just maybe — turning your labours into a cure.